Article
Rheumatology
Matthew J. Koster, Cynthia S. Crowson, Rachel E. Giblon, Jane M. Jaquith, Ali Duarte-Garcia, Eric L. Matteson, Cornelia M. Weyand, Kenneth J. Warrington
Summary: This study investigated the use of baricitinib in patients with relapsing giant cell arteritis (GCA) and found it was well tolerated, allowing for discontinued use of glucocorticoids in most patients. Larger randomized clinical trials are necessary to further evaluate the efficacy of JAK inhibition in GCA.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Huibin Kang, Xiaoyan Bai, Yisen Zhang, Wei Zhou, Yi Ju, Xinjian Yang, Binbin Sui, Chengcheng Zhu
Summary: This study aimed to investigate the predictors of improvement in patients with isolated intracranial vasculitis stenoses using high-resolution vessel wall magnetic resonance imaging (HR VW-MRI). The degree of wall enhancement at baseline was found to be an independent predictive factor associated with the improvement in intracranial vasculitis stenoses. Therefore, a lower degree of wall enhancement is more likely to result in reduced stenosis in patients undergoing conventional conservative therapy.
EUROPEAN JOURNAL OF RADIOLOGY
(2023)
Article
Rheumatology
Yann Coattrenec, Yannick D. Muller, David Spoerl, Johannes A. Lobrinus, Jorg D. Seebach
Summary: This study found that the prevalence of LVV in AAV patients is 5%, significantly higher than in the normal population, and mainly occurs in patients with GPA.
RHEUMATOLOGY INTERNATIONAL
(2021)
Article
Oncology
Reinhard Dummer, Paola Queirolo, Ana Maria Abajo Guijarro, Youyou Hu, Dao Wang, Sergio Jobim de Azevedo, Caroline Robert, Paolo Antonio Ascierto, Vanna Chiarion-Sileni, Paolo Pronzato, Francesco Spagnolo, Karmele Mujika Eizmendi, Gabriella Liszkay, Luis de la Cruz Merino, Hussein Tawbi
Summary: This study evaluated the use of atezolizumab in combination with cobimetinib or vemurafenib plus cobimetinib for patients with melanoma with CNS metastases. The results showed that the combination of atezolizumab and vemurafenib plus cobimetinib provided promising intracranial activity in patients with BRAF(V60)-mutated melanoma with CNS metastases.
Article
Medicine, General & Internal
Ben Colagiuri, Louise Sharpe, Zahava Ambarchi, Nick Glozier, Delwyn Bartlett, Daniel S. J. Costa, Amelia Scott
Summary: Insomnia is a common sleep disorder that can have significant personal and societal impacts. This study aims to compare the efficacy of open-label placebo (OLP), conventional placebo (CP), and no treatment for insomnia. The results will provide insight into the effects and predictors of uptake and responses to OLP and CP for insomnia.
Article
Multidisciplinary Sciences
Deborah A. Hall, Robin M. Voigt, Thaisa M. Cantu-Jungles, Bruce Hamaker, Phillip A. Engen, Maliha Shaikh, Shohreh Raeisi, Stefan J. Green, Ankur Naqib, Christopher B. Forsyth, Tingting Chen, Richard Manfready, Bichun Ouyang, Heather E. Rasmussen, Shahriar Sedghi, Christopher G. Goetz, Ali Keshavarzian
Summary: This study found that prebiotic intervention can beneficially change the microbiome, decrease inflammation and a marker of neurodegeneration, with possible clinical effects in Parkinson's disease (PD) patients.
NATURE COMMUNICATIONS
(2023)
Article
Clinical Neurology
Irene Cortese, Erin S. Beck, Omar Al-Louzi, Joan Ohayon, Frances Andrada, Ikesinachi Osuorah, Jenifer Dwyer, B. Jeanne Billioux, Nigar Dargah-zada, Matthew K. Schindler, Kyle Binder, Lauren Reoma, Gina Norato, Yoshimi Enose-Akahata, Bryan R. Smith, Maria Chiara Monaco, Eugene O. Major, Steven Jacobson, David Stroncek, Steven Highfill, Sandhya Panch, Daniel S. Reich, John Barrett, Avindra Nath, Pawel Muranski
Summary: The study conducted an open-label, single-cohort pilot study in patients with progressive multifocal leukoencephalopathy. The results showed that generation of polyomavirus-specific T cells from healthy related donors is feasible and these cells can be safely used for adoptive immunotherapy of progressive multifocal leukoencephalopathy. The data provide support for this strategy as a potential life-saving therapy for some patients.
Article
Oncology
Beung-Chul Ahn, Jee Hung Kim, Kyoung-Ho Pyo, Sun Min Lim, Min Hee Hong, Hye Ryun Kim, Byoung Chul Cho
Summary: This study confirmed the clinical activity and CNS efficacy of osimertinib in an unselected real-world population, indicating its potential importance for patients with EGFR mutation-positive NSCLC.
Review
Rheumatology
Javier Narvaez, Paula Estrada, Didac LLop, Paola Vidal-Montal, Emma Brugarolas, Pol Maymo-Paituvi, Judith Palacios-Olid, Joan Miquel Nolla
Summary: The effectiveness and safety of leflunomide in large vessel vasculitis were assessed through a systematic review and meta-analysis. The results showed that leflunomide was well-tolerated and effective in the treatment of Takayasu arteritis and giant cell arteritis.
SEMINARS IN ARTHRITIS AND RHEUMATISM
(2023)
Article
Hematology
Jun Ho Jang, Lily Wong, Bor-Sheng Ko, Sung-Soo Yoon, Katie Li, Irina Baltcheva, Prasanna Kumar Nidamarthy, Raghav Chawla, Guido Junge, Eng Soo Yap
Summary: Iptacopan is a novel oral inhibitor of complement factor B under development for the treatment of PNH. This phase 2 study evaluated the efficacy and safety of iptacopan in PNH patients with active hemolysis. The results showed that iptacopan effectively reduced LDH levels, improved hemolytic markers, and rapidly increased Hb levels in most patients.
Article
Immunology
Huakun Lv, Shenyu Wang, Zhenzhen Liang, Wei Yu, Chuanfu Yan, Yingping Chen, Xiaosong Hu, Rong Fu, Minghuan Zheng, Thomas Group, Alain Luxembourg, Xueyan Liao, Zhiping Chen
Summary: This study compared the immunogenicity and safety of the 9-valent human papillomavirus vaccine in different age groups of Chinese females. The results showed that the antibody responses in females aged 9-19 years and 27-45 years were non-inferior to those in females aged 20-26 years, and the vaccine was well tolerated.
Article
Oncology
Justin F. Gainor, Giuseppe Curigliano, Dong-Wan Kim, Dae Ho Lee, Benjamin Besse, Christina S. Baik, Robert C. Doebele, Philippe A. Cassier, Gilberto Lopes, Daniel S. W. Tan, Elena Garralda, Luis G. Paz-Ares, Byoung Chul Cho, Shirish M. Gadgeel, Michael Thomas, Stephen Liu, Matthew H. Taylor, Aaron S. Mansfield, Viola W. Zhu, Corinne Clifford, Hui Zhang, Michael Palmer, Jennifer Green, Christopher D. Turner, Vivek Subbiah
Summary: The study demonstrated that pralsetinib is a new, well-tolerated, promising, once-daily oral treatment option for patients with RET fusion-positive NSCLC.
Article
Oncology
Lauren R. Schaff, Mina Lobbous, Dean Carlow, Ryan Schofield, Igor T. Gavrilovic, Alexandra M. Miller, Jacqueline B. Stone, Anna F. Piotrowski, Ugur Sener, Anna Skakodub, Edward P. Acosta, Kevin J. Ryan, Ingo K. Mellinghoff, Lisa M. DeAngelis, Louis B. Nabors, Christian Grommes
Summary: This study shows the feasibility of using low-dose glucarpidase to facilitate MTX clearance in patients with CNS lymphoma, without affecting the efficacy of MTX in the CNS. The treatment was safe and well-tolerated, with radiographic responses in line with expectations.
Article
Biochemistry & Molecular Biology
Bruce J. Kirenga, Levicatus Mugenyi, Marina Sanchez-Rico, Henry Kyobe, Winters Muttamba, Raymond Mugume, Eliya Mwesigwa, Ezra Kalimo, Vicky Nyombi, Ivan Segawa, Loryndah Olive Namakula, Rogers Sekibira, Wilberforce Kabweru, Rosemary Byanyima, Hellen Aanyu, Pauline Byakika-Kibwika, Henry G. Mwebesa, Nicolas Hoertel, William Bazeyo
Summary: Prior research suggests that fluvoxamine, an SSRI used for mental disorders, may be effective against COVID-19. This study found that fluvoxamine was associated with reduced mortality and increased symptom resolution in inpatients with COVID-19. However, further research is needed to confirm these findings and assess potential side effects.
MOLECULAR PSYCHIATRY
(2023)
Article
Medicine, General & Internal
Emanuel Della-Torre, Marco Lanzillotta, Corrado Campochiaro, Giulia Di-Colo, Gaia Mancuso, Gabriele Capurso, Massimo Falconi, Lorenzo Dagna
Summary: This study evaluated the efficacy and safety of the rituximab biosimilar CT-P10 in patients with IgG4-RD, showing that 60% of patients achieved disease remission at six months. However, 36% of patients relapsed within 18 months, and 37% experienced side effects related to RTX-B administration.
EUROPEAN JOURNAL OF INTERNAL MEDICINE
(2021)
